Chronic Effects of Diltiazem Sustained-release Capsule in Patients with Coronary Slow Flow Phenomenon

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TCC-11001864

Enrollment

Unknown

Registered

2011-11-28

Start date

2004-03-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Slow Flow

Interventions

1:diltiazem sustained- release capsules treatment

2:placebo

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Eighty patient with chest pain and diagnosed as CSF using the corrected (corrected TIMI frame count, CTFC) method from 2004 to 2009 in our department were included

Exclusion criteria

Exclusion criteria: 1. A history of myocardial infarction or coronary angioplasty; 2. Cardiomyopathy, valvular disease, hypertensive heart disease, congenital heart disease; 3. Coronary artery dilatation, stenosis (stenosis> 40%); 4. Systolic blood pressure =III; 7. Liver or renal dysfunction (serum aspartate transaminase or alanine transaminase ALT increased by 2-fold, creatinine >=2mg/dL); 8. Study drug allergy.

Design outcomes

Primary

Measure	Time frame
Symptoms;	—

Countries

China

Contacts

Public ContactGu Ye

yegu2003cn@163.com+86 13971010080

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 26, 2026